What Is Dihexa? AngIV Analog, HGF/c-Met, Evidence

TL;DR: Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a small-molecule angiotensin IV analog developed at Washington State University to be orally active and blood-brain barrier permeable. Rodent model research proposed a procognitive mechanism through the hepatocyte growth factor (HGF)/c-Met receptor pathway and hippocampal synaptogenesis. The evidence base is narrow, the primary mechanistic paper was retracted, and no human clinical trials have been published. Dihexa is not FDA approved and is not for human use.

Research-Use Disclaimer: This article is for educational and research reference purposes only. Dihexa is not approved by the FDA for human use. This content does not constitute medical advice, does not recommend or endorse human administration of any compound, and does not describe protocols for personal use. All study findings described below refer to published preclinical research. For adults 21+ with a research interest only.

What Is Dihexa? Definition, Structure, and Origins

Dihexa, chemical name N-hexanoic-Tyr-Ile-(6) aminohexanoic amide, is a synthetic, low-molecular-weight analog of angiotensin IV (AngIV), a hexapeptide fragment of the renin-angiotensin system with the native sequence Val-Tyr-Ile-His-Pro-Phe. It was synthesized by researchers at Washington State University, primarily by John W. Wright and Joseph W. Harding and colleagues at the Department of Integrative Physiology and Neuroscience, as part of a long-running program to develop blood-brain barrier-permeable, metabolically stable analogs of AngIV-related molecules.

The key pharmacokinetic challenge the WSU group sought to overcome was that native AngIV and its first-generation analog Norleucine1-AngIV (Nle1-AngIV), though active in intracerebroventricular rodent studies, are peptides that are metabolically unstable and cannot cross the blood-brain barrier when administered systemically. Dihexa was engineered to address both problems: it is a non-peptide small molecule designed to be orally bioavailable and capable of penetrating the CNS. This design goal is documented in a 2014 review by Wright, Kawas, and Harding in Progress in Neurobiology (PMID 25455861), which describes Dihexa as showing “promise in overcoming memory and motor dysfunctions by augmenting synaptic connectivity via the formation of new functional synapses” in rodent models.

What Is the Brain Angiotensin IV / AT4 Receptor System?

To understand Dihexa’s proposed mechanism, researchers must first understand the foundational AngIV/AT4 receptor science that motivated its synthesis. The AT4 receptor subtype, discovered by the Wright/Harding lab in 1992, is a binding site distinct from the classical AT1 and AT2 angiotensin receptors. According to a foundational 1997 review by Wright and Harding published in Brain Research Reviews (PMID 9370053), the AT4 site is “heavily distributed in neocortex, hippocampus, cerebellum, and basal ganglia structures” and appears to mediate “memory acquisition and retrieval” as well as neurite outgrowth and regulation of blood flow in animal models.

A 2004 review in Progress in Neurobiology by the same authors (PMID 15142685) expanded on this framework, proposing that the AngIV/AT4 system interacts with brain matrix metalloproteinases to modify extracellular matrix molecules and permit “the synaptic remodeling critical to the neural plasticity presumed to underlie memory consolidation, reconsolidation, and retrieval.” The review noted that AngIV activation of the AT4 subtype has a facilitory influence on “neuronal firing rate, long-term potentiation, associative and spatial learning” in rodent models.

A 2009 review article in the Journal of the Renin-Angiotensin-Aldosterone System by Wright and Harding (PMID 19126664) specifically proposed the AT4 receptor subtype as a potential drug development target for memory dysfunction research, contextualizing it within the broader landscape of brain renin-angiotensin pharmacology. These reviews are non-retracted and constitute the foundational scientific context within which Dihexa was developed.

What Mechanism Has Dihexa Research Proposed? The HGF/c-Met Pathway

The central mechanistic hypothesis distinguishing Dihexa from earlier AngIV analogs is its proposed interaction with the hepatocyte growth factor (HGF) / c-Met receptor tyrosine kinase system, not simply the AT4 receptor. This hypothesis was the focus of the primary Dihexa-specific mechanistic study in the published literature.

The Primary Mechanistic Study and Its Retraction

The most frequently cited study specifically on Dihexa’s mechanism is Benoist et al. (2014), published in the Journal of Pharmacology and Experimental Therapeutics (PMID 25187433). That study reported that Dihexa and Nle1-AngIV bind hepatocyte growth factor (HGF) and, in the presence of subthreshold HGF concentrations, induce c-Met phosphorylation, augment HGF-dependent cell scattering, and promote hippocampal spinogenesis and synaptogenesis in rodent models. The study also reported that orally delivered Dihexa’s procognitive activity in the Morris water maze was blocked by an intracerebroventricularly delivered HGF antagonist.

Researchers must be aware that this paper is listed as a Retracted Publication in PubMed. As of the date of this article’s publication, the retraction notice is indexed in PubMed alongside the original paper. The reasons for retraction and a current retraction statement should be consulted directly via the journal. Because the primary Dihexa-specific mechanistic paper is retracted, the HGF/c-Met hypothesis as it applies specifically to Dihexa must be understood as unverified at the level of the published, peer-reviewed record. This is a material limitation that any honest evidence assessment must state plainly.

The Non-Retracted Precursor Evidence: Nle1-AngIV and Synaptogenesis

Separate from the retracted Dihexa paper, the broader class of AngIV-derived analogs, and specifically the parent compound Nle1-AngIV, has non-retracted published research supporting the general hypothesis that AngIV-related molecules can affect synaptic structure in rodent hippocampal models.

A 2011 study by Benoist, Wright, Zhu, Appleyard, Wayman, and Harding in the Journal of Pharmacology and Experimental Therapeutics (PMID 21719467) is not retracted and represents relevant precursor data. That study examined C-terminal truncated Nle1-AngIV analogs in rodent models, finding a correlation between a peptide’s procognitive activity and its capacity to increase dendritic spine numbers and enlarge spine head size in hippocampal cultures. The authors concluded that the procognitive activity of these molecules is “attributable to their ability to augment synaptic connectivity”, the structural substrate upon which Dihexa was subsequently designed to act more potently via oral delivery.

Earlier rodent behavioral pharmacology studies from the WSU group demonstrated that Nle1-AngIV reliably reverses scopolamine-induced spatial memory deficits in the circular water maze, an effect blocked by AT4 receptor antagonists. A 2001 study by Pederson, Krishnan, Harding, and Wright in Regulatory Peptides (PMID 11730987) and a 2004 study by Olson et al. in Peptides (PMID 15063004) established this behavioral pharmacology profile in rodent models. These studies concern the parent analog class, not Dihexa specifically.

What Does the AT4/AngIV Research Landscape Show? Broader Context

A 2009 rodent behavioral study by Wilson, Munn, Ross, Harding, and Wright in Brain Research (PMID 19328191) investigated the AT4 receptor in the Nucleus Basalis Magnocellularis, a major source of cholinergic innervation to cognitive brain areas. Researchers found that blocking the AT4 receptor with Divalinal-AngIV produced spatial memory deficits in rats, and that nicotinic receptor activation could reverse these impairments. The authors interpreted this as supporting “a functional role for both the cholinergic and AT4 receptor systems in spatial learning.” This is animal-model data; it does not establish human cognitive outcomes.

The most comprehensive review integrating this work and positioning it relative to neurodegeneration research contexts was published in 2019 by Wright and Harding in the Journal of Alzheimer’s Disease (PMID 30664507). That review describes the AngIV/AT4 receptor system alongside the Ang(1-7)/Mas receptor system as potentially counteracting some of the damaging influences of the classical AngII/AT1 system in brain tissue. The review notes that AT4 receptor density is decreased in the brains of individuals studied post-mortem in Alzheimer’s research contexts, and frames this as a potential drug development rationale, not as evidence that any compound prevents or treats Alzheimer’s disease. Dihexa is mentioned within this review as one candidate in the drug development program.

What Is Dihexa’s Evidence Tier? An Honest Assessment

The evidence landscape for Dihexa differs meaningfully from many other research peptides, and researchers should understand these distinctions clearly before engaging with the literature.

The critical limitation to state plainly: Dihexa’s profile is defined by the retraction of its primary mechanistic paper. This does not mean the underlying science is necessarily wrong, retractions have varied causes, but it does mean the specific mechanistic claims about Dihexa and HGF/c-Met in that paper cannot be treated as part of the verified, peer-reviewed record. The non-retracted evidence is for the parent analog class (Nle1-AngIV and related compounds), not for Dihexa specifically. Human clinical data is entirely absent. Researchers engaging with this compound should weigh the retraction as a significant limitation when assessing the published literature.

Regulatory and Doping Status

FDA (United States)

Dihexa is not approved by the U.S. Food and Drug Administration as a drug, biologic, or dietary supplement ingredient. It has no approved human indication, no authorized human dosing protocol, and is not legally available as a pharmaceutical in the United States. Researchers should consult current FDA guidance directly for its regulatory classification and any applicable import rules.

WADA (World Anti-Doping Agency)

Dihexa falls under Section S0: Non-Approved Substances on the WADA Prohibited List, the category that covers any pharmacological substance not currently approved by any governmental regulatory authority for human therapeutic use. S0 applies both in-competition and out-of-competition. Athletes subject to WADA rules are prohibited from using any S0 compound regardless of intent or context.

Comparing Dihexa to Related Cognitive-Cluster Compounds

Researchers studying the cognitive-neuropeptide space often encounter Dihexa alongside other compounds in the cluster. Key distinctions are worth stating explicitly:

• Semax (see: What Is Semax?) acts via BDNF/NGF upregulation, has a substantially larger non-retracted literature base, and is approved for clinical use in Russia. Its evidence tier is stronger than Dihexa’s.
• Selank (see: What Is Selank?) operates on the tuftsin/immune-modulation axis with anxiolytic effects documented in rodent models; also Russia-registered with a more developed preclinical literature than Dihexa.
• Cerebrolysin (see: What Is Cerebrolysin?) is a multi-factor peptide mixture with a broader human trial data set than any of the above, a meaningfully different evidence profile.
• Dihexa’s distinguishing design feature is oral bioavailability and BBB penetrance as a non-peptide small molecule, a pharmacokinetic advantage over Semax and Selank (which are administered intranasally), but this advantage is currently unvalidated beyond the retracted study and patent literature.

For a complete comparative overview of the cognitive-neuropeptide cluster, see the cognitive neuropeptides research overview.

Frequently Asked Questions About Dihexa

What is Dihexa?

Dihexa (N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a synthetic small-molecule analog of angiotensin IV developed at Washington State University to be orally bioavailable and blood-brain barrier permeable. It was designed to translate the procognitive properties attributed to the brain AngIV/AT4 receptor system into a systemically deliverable research compound. All published evidence is preclinical and concentrated at the institution of origin.

How does Dihexa work? What is the HGF/c-Met mechanism?

The proposed mechanism, that Dihexa binds HGF and potentiates c-Met receptor signaling to drive hippocampal synaptogenesis and dendritic spine growth, was reported in Benoist et al. (2014, JPET). That paper is retracted. The non-retracted precursor literature on parent compound Nle1-AngIV supports a role for AT4-related signaling in dendritic spine remodeling and spatial memory in rodent models, but the specific HGF/c-Met claims for Dihexa itself are unverified in the current peer-reviewed record.

Is Dihexa FDA approved or legal for human use?

No. Dihexa is not approved by the FDA for any therapeutic use in humans. It has no approved indication, no authorized human dosing protocol, and is not available as a licensed pharmaceutical. It is classified as a research compound. It is prohibited under WADA Section S0 for athletes subject to anti-doping rules.

What is the evidence tier for Dihexa?

Dihexa is a Tier 3 compound in the Legendary Labz framework, limited and heavily qualified preclinical evidence, with the primary mechanistic study retracted and no human clinical trials published. The non-retracted foundational science belongs to the broader AngIV/AT4 research program, not to Dihexa specifically. Researchers should consult the primary literature, including the retraction notice for PMID 25187433, before drawing conclusions about the compound’s mechanism. Full evidence-tier methodology is documented in the guide.

For educational and research reference purposes only. Not medical advice. Not for human use.